CVR: 39720213
Secondary names: hameln nordic ApS
DKK 10,300,176
Gross profit
Net result: DKK 8,050,599
hameln pharma gmbh
CVR · view ownership and management
Director role ended: Marina Alexandra Stock
CVR · 20/09/2023
View the full event history
hameln pharma ApS is a Danish company of the type Anpartsselskab based in Glostrup, founded in 2018. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Stephen Allen Watkin and Frank Jahrand. The company is owned by hameln pharma gmbh. In 2025, the company reported a gross profit of DKK 10,300,176 and a net result of DKK 8,050,599 compared with DKK 5,288,671 the year before. Equity in the 2025 report amounted to DKK 20,334,774.
Source: annual report 2025, Danish Business Authority
The financial health of hameln pharma ApS appears robust, with a consistent upward trajectory in gross profit and profit over the past five years. Gross profit increased from 1,874,153 DKK in 2021 to 10,300,176 DKK in 2025, while profit rose from 1,416,578 DKK to 8,050,599 DKK during the same period, indicating strong operational efficiency and profitability. The company's equity has also significantly improved, reaching 20,334,774 DKK in 2025, which reflects a solid capital position. However, the absence of revenue figures may raise concerns regarding transparency and overall market performance. Positioned within the pharmaceutical wholesale industry, hameln pharma ApS demonstrates strong growth potential, supported by increasing profit margins.
AI-generated summary · Generated 16/08/2026
Selskabets formål er at registrere, importere, opbevare og eksportere, sælge, markedsføre og distribuere lægemidler.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | 10.3 mio. | 8.1 mio. | 24.4 mio. | 20.3 mio. | 0 | |
| 202401/01/2024 – 31/12/2024 | 6.9 mio. | 5.3 mio. | 18.6 mio. | 12.3 mio. | 0 | |
| 202301/01/2023 – 31/12/2023 | 3.1 mio. | 2.3 mio. | 15.5 mio. | 7.4 mio. | 0 | |
| 202201/01/2022 – 31/12/2022 | 2.6 mio. | 1.9 mio. | 9.4 mio. | 5 mio. | 0 | |
| 202101/01/2021 – 31/12/2021 | 1.9 mio. | 1.4 mio. | 5.2 mio. | 3.2 mio. | 0 | |
| 202001/01/2020 – 31/12/2020 | 2.4 mio. | 1.9 mio. | 6 mio. | 1.8 mio. | 0 |
Compared to 407 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
12 public tenders won
Showing 10 of 12 contracts
See all won contracts on UdbudsScannerSources: TED (the EU tender database) and udbud.dk
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationhameln pharma ApS was founded on 9 July 2018.
hameln pharma ApS is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler (industry code 464610).
hameln pharma ApS is owned by hameln pharma gmbh.
In 2025, hameln pharma ApS reported a gross profit of DKK 10,300,176.
The management of hameln pharma ApS consists of Stephen Allen Watkin and Frank Jahrand.
hameln pharma ApS is located at Naverland 22, 2600 Glostrup.
Claim this page to add your logo and social links. Free to get started.
Hameln pharma ApS has published its annual report for 2025. Gross profit came to DKK 10,300,176, and the net result was DKK 8,050,599.
Hameln pharma ApS has won the tender "Amgros 2026 1.601.a" issued by Amgros I/S worth 331,750,548 DKK.
Hameln pharma ApS has won the tender "Amgros 2026 2.1302.b" issued by Amgros I/S worth 161,990,275 DKK.
Hameln pharma ApS has won the tender "Amgros 2026 1.615.b" issued by Amgros I/S worth 48,195,968 DKK.
Hameln pharma ApS has won the tender "Amgros 2026 1.201.a" issued by Amgros I/S worth 286,787,957 DKK.
Hameln pharma ApS has published its annual report for 2024. Gross profit came to DKK 6,856,814, and the net result was DKK 5,288,671.
Hameln pharma ApS has won the tender "Amgros 2025 1.1208.b" issued by Amgros I/S worth 7,330,000 DKK.
Hameln pharma ApS has won the tender "Amgros 2025 2.1310.b" issued by Amgros I/S worth 129,999,998 DKK.
Hameln pharma ApS has won the tender "Amgros 2025 1.1303.b" issued by Amgros I/S worth 14,267,938 DKK.
Hameln pharma ApS has won the tender "Amgros 2025 1.1302.a" issued by Amgros I/S worth 17,702,414 DKK.
Hameln pharma ApS has won the tender "Amgros 2025 1.1205.a" issued by Amgros I/S worth 73,155,425 DKK.
Hameln pharma ApS has won the tender "Amgros 2025 1.1240.a" issued by Amgros I/S worth 13,800,000 DKK.
Hameln pharma ApS has won the tender "Joint Nordic Procurement of Pharmaceuticals - 2025 - NF2.1301.a" issued by Amgros I/S worth 227,000,000 EUR.
Hameln pharma ApS has won the tender "Joint Nordic Procurement of Pharmaceuticals - 2025 - NF2.1302.a" issued by Amgros I/S worth 18,750,000 EUR.
Hameln pharma ApS has published its annual report for 2023. Gross profit came to DKK 3,130,279, and the net result was DKK 2,324,545.
As of September 20, 2023, Marina Alexandra Stock has stepped down as director of hameln pharma ApS.
Hameln pharma ApS has published its annual report for 2022. Gross profit came to DKK 2,613,040, and the net result was DKK 1,910,112.
Hameln pharma ApS has published its annual report for 2021. Gross profit came to DKK 1,874,153, and the net result was DKK 1,416,578.
Hameln pharma ApS has published its annual report for 2020. Gross profit came to DKK 2,403,938, and the net result was DKK 1,863,764.
As of July 5, 2021, Marina Alexandra Stock is registered as director of hameln pharma ApS.
As of July 5, 2021, Frank Jahrand is registered as director of hameln pharma ApS.
As of July 5, 2021, Dr. Christopher Klein has stepped down as director of hameln pharma ApS.
Hameln pharma ApS has published its interim report for the period July 9, 2018 – December 31, 2019.
As of July 9, 2018, Beierholm Godkendt Revisionspartnerselskab has been appointed auditor of hameln pharma ApS.
As of July 9, 2018, Dr. Christopher Klein is registered as director of hameln pharma ApS.
As of July 9, 2018, Stephen Allen Watkin is registered as director of hameln pharma ApS.
As of July 9, 2018, is registered as an owner of hameln pharma ApS with an ownership share of 100%.
Hameln pharma ApS was founded on July 9, 2018.
Companies in the same industry and area
CVR 26385180
CVR 32049478
CVR 36900709
CVR 83744014
CVR 28490704
